The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Neurosarcoidosis

Rare form of sarcoidosis with central and peripheral nervous system involvement.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dahiliye (İç Hastalıkları) department. Book Appointment →

What is Neurosarcoidosis?

Neurosarcoidosis is the involvement of the central and/or peripheral nervous system by non-caseating granulomas of sarcoidosis; it occurs in 5–15% of sarcoidosis patients.

Epidemiology: more frequent in adults aged 25–50 years; African-American patients have higher disease severity; 50% of patients present with neurological symptoms as initial manifestation.

Pathophysiology: T-helper-1 mediated granulomatous inflammation, with non-caseating granulomas forming in basal meninges, hypothalamus, pituitary, cranial nerves, brain parenchyma, spinal cord and peripheral nerves.

Clinical patterns: cranial neuropathy (especially facial nerve, often bilateral), aseptic meningitis, hydrocephalus, mass lesions, myelopathy, hypothalamic-pituitary dysfunction and peripheral neuropathy.

Symptoms

Cranial neuropathy (50–75%): facial nerve palsy (often bilateral), optic neuropathy, vestibulocochlear nerve involvement
Headache, meningismus, photophobia (aseptic meningitis pattern)
Seizures (focal or generalized) due to parenchymal lesions
Cognitive impairment, behavioral changes, psychiatric symptoms
Sensorimotor deficits, paraparesis, sphincter dysfunction (myelopathy)
Diabetes insipidus, panhypopituitarism, hypothalamic dysfunction (temperature dysregulation, hyperphagia)
Visual field defects, optic disc edema (intracranial hypertension or optic neuritis)
Peripheral neuropathy: sensory, motor or mixed; small-fiber neuropathy with autonomic features
Constitutional symptoms: fatigue, weight loss, fever, night sweats; pulmonary, ocular and skin involvement

Risk Factors

Established systemic sarcoidosis (5–15% develop neurosarcoidosis)
African-American ancestry (3–4× higher risk and more severe disease)
Northern European ancestry (Scandinavian and Irish populations)
Age 25–50 years at diagnosis
Female sex (slight predominance for cranial neuropathy)
Family history of sarcoidosis (5% genetic component)
Environmental exposures: occupational mold, beryllium, silica dust
HLA-DRB1 alleles (genetic susceptibility)
Active multi-organ sarcoidosis with high disease burden

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New-onset facial palsy, especially bilateral or recurrent (consider neurosarcoidosis)
  • Headache, meningitis-like symptoms, fever and stiff neck without infectious etiology
  • Seizures, focal neurological deficits or progressive cognitive decline
  • Visual changes, optic disc edema or unexplained vision loss
  • Polyuria, polydipsia or hormonal abnormalities suggesting hypothalamic-pituitary involvement
  • Progressive sensorimotor deficits, gait disturbance or sphincter dysfunction
  • Known sarcoidosis with new neurological symptoms (urgent evaluation)
  • Persistent or worsening neurological symptoms despite therapy

Treatment Methods

01
Diagnostic workup: detailed neurological examination, comprehensive history of systemic sarcoidosis manifestations, laboratory testing (ACE, calcium, IL-2 receptor)
02
MRI brain and spine with gadolinium: leptomeningeal enhancement (especially basal meninges), parenchymal T2 hyperintensities, optic nerve enhancement, hydrocephalus, mass lesions; spine MRI for myelopathy
03
Cerebrospinal fluid analysis: lymphocytic pleocytosis (5–500 cells/μL), elevated protein, low or normal glucose, elevated CSF ACE (low sensitivity), oligoclonal bands; exclude infectious and neoplastic causes
04
Tissue diagnosis: biopsy of accessible lesions (skin, lymph node, lung, conjunctiva, leptomeninges); transbronchial biopsy in patients with pulmonary involvement; demonstration of non-caseating granulomas excluding alternatives
05
Imaging extra-neurological organs: chest CT (mediastinal/hilar lymphadenopathy, parenchymal disease), PET-CT for occult disease, ophthalmologic examination, ECG/echocardiography for cardiac sarcoidosis
06
First-line therapy: oral corticosteroids (prednisolone 0.5–1 mg/kg/day for 2–4 weeks, then taper over 6–12 months); high-dose IV methylprednisolone for severe acute presentations
07
Steroid-sparing immunosuppression: methotrexate 7.5–25 mg/week, mycophenolate mofetil 1–3 g/day, or azathioprine 2–3 mg/kg/day; first-line maintenance therapy in most patients
08
TNF inhibitors (infliximab): 5 mg/kg IV at weeks 0, 2, 6, then every 4–8 weeks; effective for refractory and severe disease (myelopathy, mass lesions); preferred biologic agent
09
Adalimumab: 40 mg subcutaneously every 1–2 weeks; alternative TNF inhibitor with comparable efficacy
10
Cyclophosphamide: pulse therapy 750 mg/m² monthly for severe refractory disease (vasculitic forms, life-threatening myelopathy)
11
Hydroxychloroquine: 200–400 mg/day for skin and joint manifestations; modest neurological benefit
12
Cranial nerve palsies (especially facial): high-dose steroids with usual recovery in weeks; physical and speech therapy
13
Hydrocephalus management: ventriculoperitoneal shunting for obstructive hydrocephalus; lumbar drainage in selected cases
14
Endocrine therapy: hormone replacement (DDAVP for diabetes insipidus, levothyroxine, hydrocortisone, sex hormones, growth hormone) for hypothalamic-pituitary dysfunction
15
Anticonvulsant therapy for seizures (levetiracetam, lamotrigine, valproate); manage neuropathic pain with gabapentin or pregabalin
16
Monitoring: clinical assessment every 2–3 months during active disease, MRI every 6–12 months, CSF analysis if relapse suspected; serum ACE not reliable for activity
17
Side effect monitoring of immunosuppressive therapy: infection screening (TB, hepatitis B/C, HIV before TNF inhibitors), bone health, glucose, blood pressure, lipid panel
18
Long-term outcomes: 50–70% achieve remission with treatment; 20–30% chronic progressive course; mortality 5–10%; life-threatening forms involve hydrocephalus and brainstem disease
19
Multidisciplinary follow-up: neurology, rheumatology, pulmonology, endocrinology, ophthalmology and neurosurgery as required

Which Department to Visit?

You can visit our Dahiliye (İç Hastalıkları) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dahiliye (İç Hastalıkları) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.